Skip to main content Back to Top
Advertisement

11/8/2021

Lidocaine with Epinephrine Injection

Products Affected - Description

    • Lidocaine (with epinephrine 1:100,000) injection, Pfizer, 1%, 20 mL vial, 100 count, NDC 00409-3178-01
    • Lidocaine (with epinephrine 1:100,000) injection, Pfizer, 1%, 30 mL vial, 100 count, NDC 00409-3178-02
    • Lidocaine (with epinephrine 1:100,000) injection, Pfizer, 1%, 50 mL vial, 100 count, NDC 00409-3178-03
    • Lidocaine (with epinephrine 1:100,000) injection, Pfizer, 2%, 20 mL vial, 100 count, NDC 00409-3182-01
    • Lidocaine (with epinephrine 1:100,000) injection, Pfizer, 2%, 30 mL vial, 100 count, NDC 00409-3182-02
    • Lidocaine (with epinephrine 1:100,000) injection, Pfizer, 2%, 50 mL vial, 100 count, NDC 00409-3182-03
    • Lidocaine (with epinephrine 1:200,000) injection, Pfizer, 0.5%, 50 mL vial, 100 count, NDC 00409-3177-01
    • Lidocaine (with epinephrine 1:200,000) injection, Pfizer, 1.5%, 30 mL vial, 25 count, NDC 00409-3181-01
    • Lidocaine (with epinephrine 1:200,000) injection, Pfizer, 1.5%, 5 mL glass ampule, 10 count, NDC 00409-1209-01
    • Lidocaine (with epinephrine 1:200,000) injection, Pfizer, 2%, 20 mL vial, 25 count, NDC 00409-3183-01
    • Xylocaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 1%, 10 mL vial, 25 count, NDC 63323-0482-17
    • Xylocaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 1%, 20 mL vial, 25 count, NDC 63323-0482-27
    • Xylocaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 1%, 50 mL vial, 25 count, NDC 63323-0482-57
    • Xylocaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 2%, 20 mL vial, 25 count, NDC 63323-0483-27
    • Xylocaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 2%, 50 mL vial, 25 count, NDC 63323-0483-57
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 1%, 10 mL vial, 25 count, NDC 63323-0487-17
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 1%, 30 mL vial, sterile-pack 5 count, NDC 63323-0487-31
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 1%, 30 mL vial, 25 count, NDC 63323-0487-37
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 1.5%, 10 mL vial, 25 count, NDC 63323-0488-17
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 1.5%, 30 mL vial, sterile-pack 5 count, NDC 63323-0488-31
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 1.5%, 30 mL vial, 25 count, NDC 63323-0488-37
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 2%, 10 mL vial, 25 count, NDC 63323-0489-17
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 2%, 20 mL vial, sterile-pack 5 count, NDC 63323-0489-21
    • Xylocaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi, 2%, 20 mL vial, 25 count, NDC 63323-0489-27

Reason for the Shortage

    • Fresenius Kabi has Xylocaine with epinephrine presentations on shortage due to increased demand for the product and manufacturing delays.
    • Pfizer has lidocaine with epinephrine presentations on shortage due to manufacturing delays.

Available Products

    • Xylocaine (with epinephrine 1:200,000) injection, Fresenius Kabi, 0.5%, 50 mL vial, 25 count, NDC 63323-0481-57

Estimated Resupply Dates

    • Fresenius Kabi has 1% Xylocaine (1:200,000) 10 mL, 20 mL, and 50 mL vials on back order and the company estimates a release date of mid-December 2021. The 1% Xylocaine-MPF (1:200,000) 10 mL vials are on back order and the company cannot estimate a release date. There are short-dated 1% Xylocaine-MPF with epinephrine (1:200,000) 30 mL vials in sterile packs available with an expiration date of < 5 months. The 1% Xylocaine-MPF (1:200,000) 10 mL vials are on back order and the company estimates a release date of late-December 2021. The 1.5% Xylocaine-MPF with epinephrine (1:200,000) 10 mL vials are on back order and the company cannot estimate a release date. There are short-dated 1.5% Xylocaine-MPF with epinephrine (1:200,000) 30 mL vials available with an expiration date of < 6 months. The 1.5% Xylocaine-MPF with epinephrine (1:200,000) 30 mL vials in sterile packs are on back order and the company estimates a release date of 1st quarter 2022. The 2% Xylocaine with epinephrine (1:200,000) 20 mL vials and 50 mL vials are on back order and the company estimates a release date of mid-January 2022. The 2% Xylocaine-MPF (1:200,000) 10 mL vials are on back order and the company cannot estimate a release date. There are short-dated 2% Xylocaine-MPF (1:200,000) 20 mL vials available with an expiration date of < 6 months. The 2% Xylocaine-MPF with epinephrine (1:200,000) 20 mL vials in sterile packs are on back order and the company estimates a release date of 1st quarter 2022. Check wholesalers for inventory.
    • Pfizer has 0.5% lidocaine (1:200,000) 50 mL vials available in limited supply. The 1% lidocaine (1:100,000) 20 mL are available in limited supply. The 1% lidocaine (1:100,000) 30 mL and 50 mL vials are on back order and the company estimates a release date of November 2021. The 1.5% lidocaine (1:200,000) 30 mL vials are on back order and the company estimates a release date of July 2022. The 1.5% lidocaine (1:200,000) 5 mL glass ampules are available in limited supply. The 2% lidocaine (1:200,000) 20 mL vials are on back order and the company estimates a release date of November 2021. The 2% lidocaine (1:100,000) 20 mL, 30 mL, and 50 mL vials are on back order and the company estimates a release date of November 2021.

Updated

Updated November 8, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. Created November 16, 2011 by Jane Chandramouli, PharmD, Drug Information Specialist. © 2021, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.